Overview
OVID market data
Price History
OVID price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.24 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.25 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -240.1% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.52 – $3.11 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $476.9M · P/B 0.89 · P/S 65.76.
Company News
Ovid Therapeutics Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $733.000K Beat $30.000K EstimateBenzinga · Aug 13, 2026, 12:58 PM
Oppenheimer Maintains Outperform on Ovid Therapeutics, Raises Price Target to $9Benzinga · Aug 3, 2026, 2:25 PM
Ovid Therapeutics Promotes Charles Carter As CFO Succeeding Jeffrey RonaBenzinga · Jul 8, 2026, 11:35 AM
8-K filing — Ovid Therapeutics Inc. (OVID)SEC EDGAR · Jul 8, 2026, 11:03 AM
Rivian, Micron And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · Jul 7, 2026, 12:05 PM
uniQure's Experimental Drug Shows Early Promise In Difficult-To-Treat EpilepsyBenzinga · Jun 22, 2026, 3:55 PM